Thomas Prebet, MD, PhD, Yale School of Medicine, New Haven, CT, outlines what he’s looking forward to at this year’s virtual ASH conference. This includes greater insight into the management of molecularly-defined disease and new agents that are rising as potentially active treatments for acute myeloid leukemia (AML). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
